MLH1 and neoplasm: The median PFS for patients with a pMMR tumour, dMMR tumours caused by hypermethylation of the MLH1 promoter, and the total group of patients with a dMMR tumour, was 6.9 months (95% CI 6.3–7.7), 4.3 months (95% CI 2.4–6.6) and 4.0 months (95% CI 2.3–6.5), respectively (Figure 3).